Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Japan’s 1st Herceptin Biosimilar Now Available, but Use Limited to Gastric Cancer
Nippon Kayaku said on August 20 that it launched a biosimilar version of the major cancer drug Herceptin (trastuzumab) in Japan the same day after it won approval in March for the treatment of HER-2 overexpressing, unresectable, advanced/relapsed gastric cancer.…
To read the full story
Related Article
- Celltrion/Nippon Kayaku Herceptin Biosimilars Get OK for New Breast Cancer Dosing Schedule
August 22, 2019
- Celltrion Launches Herceptin Biosimilar in Japan
August 29, 2018
- Chugai Drops Patent Suit over Nippon Kayaku’s Herceptin Biosimilar
April 12, 2018
- Japan Approves 1st Herceptin Biosimilar for Gastric Cancer
March 26, 2018
- Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
- Chugai Sues Nippon Kayaku over Herceptin Patent
September 11, 2017
- 1st Herceptin Biosimilar Filed in Japan: Nippon Kayaku
April 12, 2017
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…